- |||||||||| cilostazol / Generic mfg.
Journal: Cilostazol Attenuates Hepatic Steatosis and Intestinal Disorders in Nonalcoholic Fatty Liver Disease. (Pubmed Central) - Jun 19, 2024 In addition, Cilostazol increased the level of short-chain fatty acids in the NAFLD mice to a level similar to that in the blank Control group. Cilostazol reduces liver lipid accumulation in NAFLD mice by improving glucose and lipid metabolism disorders and intestinal dysfunction, thereby achieving the purpose of treating NAFLD.
- |||||||||| Review, Journal: Understanding Antithrombotic Agents for Rehabilitation Therapy: A Comprehensive Narrative Review. (Pubmed Central) - May 16, 2024
Antiplatelet agents include aspirin, clopidogrel, ticlopidine, prasugrel, ticagrelor, and cilostazol...Anticoagulants include heparin, synthetic Xa inhibitors, direct oral anticoagulants (DOACs), synthetic antithrombin agents, and warfarin...With regard to ischemic cerebrovascular disease (ICD) and antithrombotic agents, the first step is to classify cerebral infarction and to determine whether antiplatelet agents or anticoagulants should be used. Bleeding and recurrence prevention are important considerations in the selection of appropriate antithrombotic agents for the pathophysiology of ICD.
- |||||||||| cilostazol / Generic mfg.
Trial completion date, Trial primary completion date: Cilostazol and Methotrexate in Rheumatoid Arthritis (clinicaltrials.gov) - Apr 9, 2024 P3, N=70, Recruiting, Long-acting cilostazol provides more intensive control of angina within 1?week, suggesting that it may be an initial choice for the treatment of VSA. Trial completion date: Feb 2024 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
- |||||||||| cilostazol / Generic mfg.
Preclinical, Journal: Protective effect of cilostazol on vascular injury in rats with acute ischemic stroke complicated with chronic renal failure. (Pubmed Central) - Mar 25, 2024 In conclusion, our results confirmed that cilostazol exerted a protective effect on the brain and kidney function, specifically in vascular injury, oxidative stress, cell apoptosis, cell autophagy, and inflammation response in CRF combined with stroke rats which were related to the upregulation of JAK/STAT3/mTOR signal pathway. The online version contains supplementary material available at 10.1007/s43188-023-00217-w.
- |||||||||| ticagrelor / Generic mfg., cilostazol / Generic mfg.
Trial completion date, Trial primary completion date: Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke (clinicaltrials.gov) - Mar 21, 2024 P3, N=580, Recruiting, accumulation, enhanced cognitive functions of the aged mice, but improved patient compliance as well, which provided a clinically accessible therapeutic strategy toward aged Alzheimer's diseases. Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
- |||||||||| oxaliplatin / Generic mfg., cilostazol / Generic mfg.
CILOSTAZOLE IMPROVES THA PROGNOSIS AFTER PARTIAL HEPATECTOMY BY PRESERVING ENDOTHELIAL CELL INTEGRITY IN RATS WITH SINUSOIDAL OBSTRUCTION SYNDROME (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5892; This study aimed to investigate the effects of cilostazol (CZ), an orally administered selective phosphodiesterase-III inhibitor, on hepatectomy in a rat SOS model...The survival rate 10 days after hepatectomy was significantly higher in the MCT + CZ group than in the MCT group (88.9% vs. 33.3%, p = 0.001, Figure 2). Conclusion : Preoperative administration of CZ improved the survival rate after partial hepatectomy by preserving LSECs in a rat SOS model.
- |||||||||| cilostazol / Generic mfg.
Review, Journal: No-reflow after recanalization in ischemic stroke: From pathomechanisms to therapeutic strategies. (Pubmed Central) - Feb 29, 2024 Prevention or treatment strategies aim to alleviate or reverse these pathological changes, including targeted therapies such as cilostazol, adhesion molecule blocking antibodies, peroxisome proliferator-activated receptors (PPARs) activator, adenosine, pericyte regulators, as well as adjunctive therapies, such as extracorporeal counterpulsation, ischemic preconditioning, and alternative or complementary therapies. Herein, we provide an overview of pathomechanisms, predictive factors, diagnosis, and intervention strategies for no-reflow, and attempt to convey a new perspective on the clinical management of no-reflow post-ischemic stroke.
- |||||||||| cilostazol / Generic mfg.
Enrollment closed: Evaluate the Efficacy and Safety of the Cilostazol-coated BioMimics 3D Stent System in Patients With Peripheral Arterial Occlusive Disease (clinicaltrials.gov) - Feb 28, 2024 P=N/A, N=24, Active, not recruiting, Herein, we provide an overview of pathomechanisms, predictive factors, diagnosis, and intervention strategies for no-reflow, and attempt to convey a new perspective on the clinical management of no-reflow post-ischemic stroke. Recruiting --> Active, not recruiting
- |||||||||| dipyridamole / Generic mfg., cilostazol / Generic mfg., desloratadine / Generic mfg.
New P2 trial: Antiplatelet Therapy in Chronic Urticaria (clinicaltrials.gov) - Feb 20, 2024 P2, N=12, Active, not recruiting,
- |||||||||| cilostazol / Generic mfg.
Cilostazol Protects Against Lung Endothelial Barrier Dysfunction Caused by MRSA (San Diego Convention Center, Area A (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_3964; Cilostazol could represent a new therapeutic strategy for bacterial-induced ARDS. Future studies will explore the molecular mechanisms by which cilostazol exerts its protective effects.
- |||||||||| Pivlaz (clazosentan) / Idorsia, Sosei
Journal: Pharmacotherapy in SAH: Clinical Trial Lessons. (Pubmed Central) - Jan 20, 2024 However, extensive research is currently underway to identify novel substances with magnesium sulphate, cilostazol, clazosentan and fasudil, demonstrating promising results...Statins may benefit some patients by reducing the incidence of vasospasm and delayed ischemic events. As several clinical trials are underway, it is expected that in the years to come, more therapeutic options will be added to the attending physician's armamentarium.
|